JP3737801B2 - プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物 - Google Patents

プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物 Download PDF

Info

Publication number
JP3737801B2
JP3737801B2 JP2002533858A JP2002533858A JP3737801B2 JP 3737801 B2 JP3737801 B2 JP 3737801B2 JP 2002533858 A JP2002533858 A JP 2002533858A JP 2002533858 A JP2002533858 A JP 2002533858A JP 3737801 B2 JP3737801 B2 JP 3737801B2
Authority
JP
Japan
Prior art keywords
pravastatin
solution
pravastatin sodium
ammonium salt
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002533858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510817A (ja
JP2004510817A5 (https=
Inventor
ケリ，ビルモシュ
デアク，ラヨス
フォルガチ，イロナ
サボ，チャバ
エディト ナジネ，アルバイ
Original Assignee
テバ ジョジセルジャール レースベニュタールシャシャーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3737801(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テバ ジョジセルジャール レースベニュタールシャシャーグ filed Critical テバ ジョジセルジャール レースベニュタールシャシャーグ
Publication of JP2004510817A publication Critical patent/JP2004510817A/ja
Publication of JP2004510817A5 publication Critical patent/JP2004510817A5/ja
Application granted granted Critical
Publication of JP3737801B2 publication Critical patent/JP3737801B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002533858A 2000-10-05 2001-10-05 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物 Expired - Fee Related JP3737801B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
PCT/US2001/031230 WO2002030415A1 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2004278522A Division JP2005013238A (ja) 2000-10-05 2004-09-24 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2005237299A Division JP2006036781A (ja) 2000-10-05 2005-08-18 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法

Publications (3)

Publication Number Publication Date
JP2004510817A JP2004510817A (ja) 2004-04-08
JP2004510817A5 JP2004510817A5 (https=) 2005-10-20
JP3737801B2 true JP3737801B2 (ja) 2006-01-25

Family

ID=22897222

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2002533858A Expired - Fee Related JP3737801B2 (ja) 2000-10-05 2001-10-05 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
JP2004278522A Withdrawn JP2005013238A (ja) 2000-10-05 2004-09-24 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2005237299A Pending JP2006036781A (ja) 2000-10-05 2005-08-18 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2009191951A Withdrawn JP2009268479A (ja) 2000-10-05 2009-08-21 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2013011711A Withdrawn JP2013128486A (ja) 2000-10-05 2013-01-25 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2015152088A Pending JP2015212300A (ja) 2000-10-05 2015-07-31 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2004278522A Withdrawn JP2005013238A (ja) 2000-10-05 2004-09-24 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2005237299A Pending JP2006036781A (ja) 2000-10-05 2005-08-18 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2009191951A Withdrawn JP2009268479A (ja) 2000-10-05 2009-08-21 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2013011711A Withdrawn JP2013128486A (ja) 2000-10-05 2013-01-25 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2015152088A Pending JP2015212300A (ja) 2000-10-05 2015-07-31 プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法

Country Status (18)

Country Link
EP (1) EP1330245A4 (https=)
JP (6) JP3737801B2 (https=)
KR (1) KR20030059173A (https=)
CN (1) CN1468098A (https=)
AU (1) AU2002211462A1 (https=)
CA (1) CA2422744A1 (https=)
CZ (1) CZ20031166A3 (https=)
HR (1) HRP20030347A2 (https=)
HU (1) HUP0400913A2 (https=)
IL (1) IL155194A0 (https=)
IS (1) IS6766A (https=)
MX (1) MXPA03002963A (https=)
NO (1) NO20031532L (https=)
NZ (1) NZ525631A (https=)
PL (1) PL361230A1 (https=)
SK (1) SK5232003A3 (https=)
WO (1) WO2002030415A1 (https=)
ZA (1) ZA200302313B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036781A (ja) * 2000-10-05 2006-02-09 Teva Gyogyszergyar Rt プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1265604T1 (sl) * 1999-11-30 2007-04-30 Sag Teva Gyogyszergyar Zartkoe Postopek za ponovno pridobivanje statinskih spojin iz fermentacije brozge
JP3881240B2 (ja) * 1999-11-30 2007-02-14 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 醗酵ブロスからスタチン化合物を回収するための方法
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
SK8312002A3 (en) 1999-12-14 2003-05-02 Biogal Gyogyszergyar Novel forms of pravastatin sodium
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546377A1 (en) 2003-11-24 2005-06-09 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method of purifying pravastatin
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
ES2254028B1 (es) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de pravastatina sodica purificada.
CA2599458A1 (en) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Process of purifying tadalafil
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN114031496B (zh) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (https=) * 1973-09-29 1977-06-11
YU40452B (en) * 1975-02-07 1986-02-28 Beecham Group Plc Process for the elimination of contaminating impurities from clavulinic acid
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
JPS5890509A (ja) * 1981-11-25 1983-05-30 Sankyo Co Ltd 高コレステロ−ル血症治療用組成物
JPH01190661A (ja) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk ４，４′−ジヒドロキシジフエニルスルホンの精製法
JP2739328B2 (ja) * 1988-09-14 1998-04-15 日本ケミファ株式会社 ベンズイミダゾール化合物の精製方法
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (ja) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd 光学活性α−カルバモイルアルカン酸誘導体およびその製法
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
AU677890B2 (en) * 1994-03-31 1997-05-08 Danisco Cultor America, Inc. Process for natamycin recovery
ATE189804T1 (de) * 1995-08-03 2000-03-15 Dsm Nv Selektives verfahren zur deacylierung von acylverbindungen
JPH09124655A (ja) * 1995-11-01 1997-05-13 Sankyo Co Ltd 新規スクアレンシンターゼ阻害活性化合物
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
JP2000229855A (ja) * 1998-12-07 2000-08-22 Satoshi Takebe プラバスタチンナトリウム錠
SK10932001A3 (sk) * 1999-02-03 2002-06-04 Institute For Drug Research Ltd. Mikrobiálny spôsob výroby pravastatínu
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
JP3881240B2 (ja) * 1999-11-30 2007-02-14 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 醗酵ブロスからスタチン化合物を回収するための方法
CN1468098A (zh) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036781A (ja) * 2000-10-05 2006-02-09 Teva Gyogyszergyar Rt プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
JP2013128486A (ja) * 2000-10-05 2013-07-04 Teva Gyogyszergyar Zartkoruen Mukodo Rt プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法

Also Published As

Publication number Publication date
WO2002030415A9 (en) 2002-10-31
PL361230A1 (en) 2004-10-04
JP2009268479A (ja) 2009-11-19
KR20030059173A (ko) 2003-07-07
JP2013128486A (ja) 2013-07-04
NZ525631A (en) 2005-05-27
JP2005013238A (ja) 2005-01-20
JP2006036781A (ja) 2006-02-09
JP2004510817A (ja) 2004-04-08
MXPA03002963A (es) 2005-01-25
NO20031532D0 (no) 2003-04-04
EP1330245A1 (en) 2003-07-30
ZA200302313B (en) 2004-03-25
NO20031532L (no) 2003-04-04
AU2002211462A1 (en) 2002-04-22
IL155194A0 (en) 2003-11-23
EP1330245A4 (en) 2004-10-20
HUP0400913A2 (en) 2006-11-28
HRP20030347A2 (en) 2005-04-30
CA2422744A1 (en) 2002-04-18
JP2015212300A (ja) 2015-11-26
SK5232003A3 (en) 2004-06-08
WO2002030415A1 (en) 2002-04-18
IS6766A (is) 2003-04-01
CZ20031166A3 (cs) 2004-04-14
CN1468098A (zh) 2004-01-14

Similar Documents

Publication Publication Date Title
JP2015212300A (ja) プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
US6689590B2 (en) Process for recovering statin compounds from a fermentation broth
US6936731B2 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP2009161542A (ja) プラバスタチンの精製方法
US20050215636A1 (en) Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
CA2581031A1 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
EP1481674B1 (en) Process for recovering statin compounds from a fermentation broth
EP1798214A1 (en) Process for recovering statin compounds from a fermentation broth
MXPA06005819A (en) Method of purifying pravastatin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040129

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20040129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040218

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20040317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040924

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20040924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050728

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051027

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081104

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091104

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091104

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101104

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111104

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121104

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131104

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees